These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

578 related items for PubMed ID: 21916908

  • 1. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
    Lai PS, Chua SS, Chew YY, Chan SP.
    J Clin Pharm Ther; 2011 Oct; 36(5):557-67. PubMed ID: 21916908
    [Abstract] [Full Text] [Related]

  • 2. Pharmaceutical care issues encountered by post-menopausal osteoporotic women prescribed bisphosphonates.
    Lai PS, Chua SS, Chan SP.
    J Clin Pharm Ther; 2012 Oct; 37(5):536-43. PubMed ID: 22380577
    [Abstract] [Full Text] [Related]

  • 3. Impact of pharmaceutical care on knowledge, quality of life and satisfaction of postmenopausal women with osteoporosis.
    Lai PS, Chua SS, Chan SP.
    Int J Clin Pharm; 2013 Aug; 35(4):629-37. PubMed ID: 23677816
    [Abstract] [Full Text] [Related]

  • 4. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD.
    Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
    [Abstract] [Full Text] [Related]

  • 5. A dedicated Fracture Liaison Service telephone program and use of bone turnover markers for evaluating 1-year persistence with oral bisphosphonates.
    van den Berg P, van Haard PMM, van der Veer E, Geusens PP, van den Bergh JP, Schweitzer DH.
    Osteoporos Int; 2018 Apr; 29(4):813-824. PubMed ID: 29260291
    [Abstract] [Full Text] [Related]

  • 6. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, Walsh JS, Eastell R.
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J, Takeda T, Sato Y.
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [Abstract] [Full Text] [Related]

  • 8. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
    Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM.
    Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
    [Abstract] [Full Text] [Related]

  • 9. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA, Amonkar MM, Hebborn A, Altman R.
    Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
    [Abstract] [Full Text] [Related]

  • 10. Low incidence of anti-osteoporosis treatment after hip fracture.
    Rabenda V, Vanoverloop J, Fabri V, Mertens R, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY.
    J Bone Joint Surg Am; 2008 Oct; 90(10):2142-8. PubMed ID: 18829912
    [Abstract] [Full Text] [Related]

  • 11. Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
    Bahlous A, Bouzid K, Sahli H, Sallami S, Abdelmoula J.
    Tunis Med; 2009 Jun; 87(6):380-1. PubMed ID: 19927782
    [Abstract] [Full Text] [Related]

  • 12. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P.
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [Abstract] [Full Text] [Related]

  • 13. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate.
    Muñoz-Torres M, Reyes-García R, Mezquita-Raya P, Fernández-García D, Alonso G, Luna Jde D, Ruiz-Requena ME, Escobar-Jiménez F.
    Maturitas; 2009 Nov 20; 64(3):188-92. PubMed ID: 19819089
    [Abstract] [Full Text] [Related]

  • 14. Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
    Palacios S, Agodoa I, Bonnick S, Van den Bergh JP, Ferreira I, Ho PR, Brown JP.
    J Clin Endocrinol Metab; 2015 Mar 20; 100(3):E487-92. PubMed ID: 25514106
    [Abstract] [Full Text] [Related]

  • 15. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
    Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE, Fosamax Actonel Comparison Trial Investigators.
    J Bone Miner Res; 2005 Jan 20; 20(1):141-51. PubMed ID: 15619680
    [Abstract] [Full Text] [Related]

  • 16. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D.
    Appl Health Econ Health Policy; 2013 Oct 20; 11(5):485-97. PubMed ID: 23868102
    [Abstract] [Full Text] [Related]

  • 17. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
    Ringe JD, Möller G.
    Rheumatol Int; 2009 Dec 20; 30(2):213-21. PubMed ID: 19430791
    [Abstract] [Full Text] [Related]

  • 18. The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis.
    Karadag-Saygi E, Akyuz G, Bizargity P, Ay P.
    Gynecol Endocrinol; 2011 Dec 20; 27(12):1033-6. PubMed ID: 21627558
    [Abstract] [Full Text] [Related]

  • 19. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis.
    Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD, Grauer A, Cahall D, Watts NB, Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators.
    J Clin Endocrinol Metab; 2007 Apr 20; 92(4):1296-304. PubMed ID: 17244788
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR, Graham CN, Ettinger B, Amonkar MM, Lynch NO, Middelhoven H.
    Curr Med Res Opin; 2007 Oct 20; 23(10):2517-29. PubMed ID: 17825128
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.